Hepatocellular carcinoma epidemiology

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 5, 2014, Pages 753-770

  Bosetti, Cristina ^a   Turati, Federica ^a   La Vecchia, Carlo ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Epidemiology; Hepatitis virus; Hepatocellular cancer; Liver cancer; Risk factors

Indexed keywords

AFLATOXIN; AFLATOXIN B1; AFLATOXIN B2; AFLATOXIN G1; AFLATOXIN G2; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS VACCINE; ORAL CONTRACEPTIVE AGENT; SOMATOMEDIN C;

AFRICA; ALCOHOL CONSUMPTION; APOPTOSIS; ASIA; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CASE CONTROL STUDY; CELL PROLIFERATION; COFFEE; DRINKING BEHAVIOR; EUROPE; FAMILY HISTORY; FEMALE; FOOD CONTAMINATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEREDITY; HIGH RISK POPULATION; HUMAN; JAPAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FUNCTION; MALE; META ANALYSIS (TOPIC); OBESITY; PERSISTENT INFECTION; PREVALENCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SEX DIFFERENCE; SMOKING; UNITED STATES; UPREGULATION; VACCINATION; CARCINOMA, HEPATOCELLULAR; HEALTH; LIVER NEOPLASMS; RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; FEMALE; GLOBAL HEALTH; HUMANS; LIVER NEOPLASMS; MALE; RISK FACTORS;

EID: 84921764363     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.08.007     Document Type: Review

References (155)

1. Percy C, Ries LG, Van Holten VD. The accuracy of liver cancer as the underlying cause of death on death certificates. Public Health Rep 1990; 105: 361-7.
2. London WT, McGlynn KA. Liver cancer. In: Schottenfeld D, Fraumeni Jr. JF, editors. Cancer epidemiology and prevention. 3rd ed. New York: Oxford University Press; 2006. p. 763-86.
3. Stuver S, Trichopolous D. Cancer of the liver and biliary tract. In: Adami HO, Hunter D, Trichopolous D, editors. Textbook of cancer epidemiology. 2rd ed. New york: Oxford University Press; 2008. p. 308-32.
4. Boffetta P, Boccia S, La Vecchia C. Cancer of the liver and biliary tract. In: Boffetta P, Boccia S, La Vecchia C, editors. A quick guide to cancer epidemiology. Springer; 2014.
5. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
6. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-91.
7. Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2011; 20: 2362-8.
8. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
9. Fan JH,Wang JB, Jiang Y, XiangW, Liang H,WeiWQ, et al. Attributable causes of liver cancer mortality and incidence in China. Asian Pac J Cancer Prev 2013; 14: 7251-6.
10. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999-2007 by country and age: Results of EUROCAREe5-A population-based study. Lancet Oncol 2014; 15: 23-34.
11. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
12. Chuang SC, La Vecchia C, Boffetta P. Liver cancer: Descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett 2009; 286: 9-14.
13. La Vecchia C, Lucchini F, Franceschi S, Negri E, Levi F. Trends in mortality from primary liver cancer in Europe. Eur J Cancer 2000; 36: 909-15.
14. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008; 48: 137-45.
15. Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, La Vecchia C. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol 2013; 24: 1667-74.
16. Franceschi S, Raza SA. Epidemiology and prevention of hepatocellular carcinoma. Cancer Lett 2009; 286: 5-8.
17. Dal Maso L, Lise M, Zambon P, Crocetti E, Serraino D, Ricceri F, et al. Incidence of primary liver cancer in Italy between 1988 and 2002: An age-period-cohort analysis. Eur J Cancer 2008; 44: 285-92.
18. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med 2003; 139: 817-23.
19. Wang P, Kang D, CaoW,Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: A systematic review and meta-analysis. Diabetes Metab Res Rev 2012; 28: 109-22.
20. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Hepatitis viruses, vol. 59. Lyon: International Agency for Research on Cancer; 1994.
21. Mori M, Hara M, Wada I, Hara T, Yamamoto K, Honda M, et al. Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. Am J Epidemiol 2000; 151: 131-9.
22. Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight-year follow-up of the 90,000-person Haimen city cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev 2002; 11: 369-76.
23. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B - antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
24. Franceschi S, Montella M, Polesel J, La Vecchia C, Crispo A, Dal Maso L, et al. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev 2006; 15: 683-9.
25. Munoz N, Lingao A, Lao J, Esteve J, Viterbo G, Domingo EO, et al. Patterns of familial transmission of HBV and the risk of developing liver cancer: A case-control study in the Philippines. Int J Cancer 1989; 44: 981-4.
26. Kuper H, Hsieh C, Stuver SO, Mucci LA, Tzonou A, Zavitsanos X, et al. Birth order, as a proxy for age at infection, in the etiology of hepatocellular carcinoma. Epidemiology 2000; 11: 680-3.
27. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004; 127: S5-16.
28. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-44.
29. Tagger A, Donato F, Ribero ML, Chiesa R, Portera G, Gelatti U, et al. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: The role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 1999; 81: 695-9.
30. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, et al. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155: 323-31.
31. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75: 347-54.
32. La Vecchia C, Negri E, Cavalieri d'Oro L, Franceschi S. Liver cirrhosis and the risk of primary liver cancer. Eur J Cancer Prev 1998; 7: 315-20.
33. Liang TJ, Ghany MG. Therapy of hepatitis Ceback to the future. N Engl J Med 2014; 370: 2043-7.
34. Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. A meta-analysis of alcohol drinking and cancer risk. Br J Cancer 2001; 85: 1700-5.
35. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Alcohol consumption and ethyl carbamate, vol. 96. Lyon: International Agency for Research on Cancer; 2010.
36. Jee SH, Ohrr H, Sull JW, Samet JM. Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. J Natl Cancer Inst 2004; 96: 1851-6.
37. Joshi S, Song YM, Kim TH, Cho SI. Socio-economic status and the risk of liver cancer mortality: A prospective study in Korean men. Public Health 2008; 122: 1144-51.
38. Kim MK, Ko MJ, Han JT. Alcohol consumption and mortality from all-cause and cancers among 1.34 million Koreans: The results from the Korea national health insurance corporation's health examinee cohort in 2000. Cancer Causes Control 2010; 21: 2295-302.
39. Shimazu T, Sasazuki S, Wakai K, Tamakoshi A, Tsuji I, Sugawara Y, et al. Alcohol drinking and primary liver cancer: A pooled analysis of four Japanese cohort studies. Int J Cancer 2012; 130: 2645-53.
40. Yang L, Zhou M, Sherliker P, Cai Y, Peto R, Wang L, et al. Alcohol drinking and overall and cause-specific mortality in China: Nationally representative prospective study of 220,000 men with 15 years of follow-up. Int J Epidemiol 2012; 41: 1101-13.
41. Persson EC, Schwartz LM, Park Y, Trabert B, Hollenbeck AR, Graubard BI, et al. Alcohol consumption, folate intake, hepatocellular carcinoma, and liver disease mortality. Cancer Epidemiol Biomarkers Prev 2013; 22: 415-21.
42. Allen NE, Beral V, Casabonne D, Kan SW, Reeves GK, Brown A, et al. Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst 2009; 101: 296-305.
43. Schutze M, Boeing H, Pischon T, Rehm J, Kehoe T, Gmel G, et al. Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study. BMJ 2011; 342: D1584.
44. Turati F, Galeone C, Rota M, Pelucchi C, Negri E, Bagnardi V, et al. Alcohol and liver cancer: A systematic review and meta-analysis of prospective studies. Ann Oncol 2014; 25: 1526-35.
45. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, et al. Light alcohol drinking and cancer: A meta-analysis. Ann Oncol 2013; 24: 301-8.
46. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Tobacco smoke and involuntary smoking, vol. 83. Lyon: International Agency for Research on Cancer; 2004.
47. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Personal habits and indoor combustions, vol. 100E. Lyon: IARC; 2012.
48. Lee YC, Cohet C, Yang YC, Stayner L, Hashibe M, Straif K. Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol 2009; 38: 1497-511.
49. Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT, et al. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: Case-control study. Int J Cancer 2008; 123: 1883-91.
50. Batty GD, Kivimaki M, Gray L, Smith GD, Marmot MG, Shipley MJ. Cigarette smoking and site-specific cancer mortality: Testing uncertain associations using extended follow-up of the original Whitehall study. Ann Oncol 2008; 19: 996-1002.
51. Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: A nested caseecontrol study. J Natl Cancer Inst 2011; 103: 1686-95.
52. KohWP, Robien K,Wang R, Govindarajan S, Yuan JM, Yu MC. Smoking as an independent risk factor for hepatocellular carcinoma: The Singapore Chinese Health Study. Br J Cancer 2011; 105: 1430-5.
53. Yuan JM, Govindarajan S, Arakawa K, Yu MC. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer 2004; 101: 1009-17.
54. Wang LY, You SL, Lu SN, Ho HC,Wu MH, Sun CA, et al. Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: A cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes Control 2003; 14: 241-50.
55. Trichopoulos D, Day NE, Kaklamani E, Tzonou A, Munoz N, Zavitsanos X, et al. Hepatitis B virus, tobacco smoking and ethanol consumption in the etiology of hepatocellular carcinoma. Int J Cancer 1987; 39: 45-9.
56. Lam KC, Yu MC, Leung JW, Henderson BE. Hepatitis B virus and cigarette smoking: Risk factors for hepatocellular carcinoma in Hong Kong. Cancer Res 1982; 42: 5246-8.
57. Tanaka K, Hirohata T, Takeshita S. Blood transfusion, alcohol consumption, and cigarette smoking in causation of hepatocellular carcinoma: A caseecontrol study in Fukuoka. Jpn Jpn J Cancer Res 1988; 79: 1075-82.
58. Tu JT, Gao RN, Zhang DH, Gu BC. Hepatitis B virus and primary liver cancer on Chongming Island, People's Republic of China. Natl Cancer Inst Monogr 1985; 69: 213-5.
59. Oshima A, Tsukuma H, Hiyama T, Fujimoto I, Yamano H, Tanaka M. Follow-up study of HBs Ag-positive blood donors with special reference to effect of drinking and smoking on development of liver cancer. Int J Cancer 1984; 34: 775-9.
60. Chuang SC, Lee YC, Hashibe M, Dai M, Zheng T, Boffetta P. Interaction between cigarette smoking and hepatitis B and C virus infection on the risk of liver cancer: A meta-analysis. Cancer Epidemiol Biomarkers Prev 2010; 19: 1261-8.
61. Williams JH, Phillips TD, Jolly PE, Stiles JK, Jolly CM, Aggarwal D. Human aflatoxicosis in developing countries: A review of toxicology, exposure, potential health consequences, and interventions. Am J Clin Nutr 2004; 80: 1106-22.
62. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-31.
63. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene, vol. 82. Lyon: International Agency for Research on Cancer; 2002.
64. Liu Y, Chang CC, Marsh GM, Wu F. Population attributable risk of aflatoxin-related liver cancer: Systematic review and meta-analysis. Eur J Cancer 2012; 48: 2125-36.
65. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994; 3: 3-10.
66. Chen JG, Egner PA, Ng D, Jacobson LP, Munoz A, Zhu YR, et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res (Phila) 2013; 6: 1038-45.
67. Srivatanakul P, Parkin DM, Khlat M, Chenvidhya D, Chotiwan P, Insiripong S, et al. Liver cancer in Thailand. II. A caseecontrol study of hepatocellular carcinoma. Int J Cancer 1991; 48: 329-32.
68. Hirayama T. Life-style and mortality: A large-scale census-based cohort study in Japan. In: Wahrendorf J, editor. Contributions to epidemiology and biostatistics. Basel, Switzerland: Karger; 1990. p. 84-5.
69. Yu MW, Chen CJ. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 1993; 53: 790-4.
70. Yu MW, Hsieh HH, Pan WH, Yang CS, CJ CH. Vegetable consumption, serum retinol level, and risk of hepatocellular carcinoma. Cancer Res 1995; 55: 1301-5.
71. Zhang W, Xiang YB, Li HL, Yang G, Cai H, Ji BT, et al. Vegetable-based dietary pattern and liver cancer risk: Results from the Shanghai women's and men's health studies. Cancer Sci 2013; 104: 1353-61.
72. Kurahashi N, Inoue M, Iwasaki M, Tanaka Y, Mizokami M, Tsugane S. Vegetable, fruit and antioxidant nutrient consumption and subsequent risk of hepatocellular carcinoma: A prospective cohort study in Japan. Br J Cancer 2009; 100: 181-4.
73. Braga C, La Vecchia C, Negri E, Franceschi S. Attributable risks for hepatocellular carcinoma in northern Italy. Eur J Cancer 1997; 33: 629-34.
74. Sauvaget C, Nagano J, Hayashi M, Spencer E, Shimizu Y, Allen N. Vegetables and fruit intake and cancer mortality in the Hiroshima/Nagasaki Life Span Study. Br J Cancer 2003; 88: 689-94.
75. Negri E, La Vecchia C, Franceschi S, D'Avanzo B, Parazzini F. Vegetable and fruit consumption and cancer risk. Int J Cancer 1991; 48: 350-4.
76. Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H, et al. Dietary habits and risk of death due to hepatocellular carcinoma in a large scale cohort study in Japan. Univariate analysis of JACC study data. Kurume Med J 2004; 51: 141-9.
77. Talamini R, Polesel J, Montella M, Dal Maso L, Crispo A, Tommasi LG, et al. Food groups and risk of hepatocellular carcinoma: A multicenter case-control study in Italy. Int J Cancer 2006; 119: 2916-21.
78. Kanazir M, Boricic I, Delic D, Tepavcevic DK, Knezevic A, Jovanovic T, et al. Risk factors for hepatocellular carcinoma: A case-control study in Belgrade (Serbia) . Tumori 2010; 96: 911-7.
79. Hadziyannis S, Tabor E, Kaklamani E, Tzonou A, Stuver S, Tassopoulos N, et al. A case-control study of hepatitis B and C virus infections in the etiology of hepatocellular carcinoma. Int J Cancer 1995; 60: 627-31.
80. Kuper H, Tzonou A, Lagiou P, Mucci LA, Trichopoulos D, Stuver SO, et al. Diet and hepatocellular carcinoma: A caseecontrol study in Greece. Nutr Cancer 2000; 38: 6-12.
81. Freedman ND, Cross AJ, McGlynn KA, Abnet CC, Park Y, Hollenbeck AR, et al. Association of meat and fat intake with liver disease and hepatocellular carcinoma in the NIH-AARP cohort. J Natl Cancer Inst 2010; 102: 1354-65.
82. Cross AJ, Leitzmann MF, Gail MH, Hollenbeck AR, Schatzkin A, Sinha R. A prospective study of red and processed meat intake in relation to cancer risk. PLoS Med 2007; 4: E325.
83. Fukuda K, Shibata A, Hirohata I, Tanikawa K, Yamaguchi G, Ishii M. A hospital-based case-control study on hepatocellular carcinoma in Fukuoka and Saga Prefectures, northern Kyushu. Jpn Jpn J Cancer Res 1993; 84: 708-14.
84. La Vecchia C, Negri E, Decarli A, D'Avanzo B, Franceschi S. Risk factors for hepatocellular carcinoma in northern Italy. Int J Cancer 1988; 42: 872-6.
85. Fedirko V, Trichopolou A, Bamia C, Duarte-Salles T, Trepo E, Aleksandrova K, et al. Consumption of fish and meats and risk of hepatocellular carcinoma: The European Prospective Investigation into Cancer and Nutrition (EPIC) . Ann Oncol 2013; 24: 2166-73.
86. Daniel CR, Cross AJ, Graubard BI, Hollenbeck AR, Park Y, Sinha R. Prospective investigation of poultry and fish intake in relation to cancer risk. Cancer Prev Res Phila 2011; 4: 1903-11.
87. Hsing AW, Guo W, Chen J, Li JY, Stone BJ, Blot WJ, et al. Correlates of liver cancer mortality in China. Int J Epidemiol 1991; 20: 54-9.
88. Yu SZ, Huang XE, Koide T, Cheng G, Chen GC, Harada K, et al. Hepatitis B and C viruses infection, lifestyle and genetic polymorphisms as risk factors for hepatocellular carcinoma in Haimen, China. Jpn J Cancer Res 2002; 93: 1287-92.
89. Sawada N, Inoue M, Iwasaki M, Sasazuki S, Shimazu T, Yamaji T, et al. Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology 2012; 142: 1468-75.
90. Fernandez E, Chatenoud L, La Vecchia C, Negri E, Franceschi S. Fish consumption and cancer risk. Am J Clin Nutr 1999; 70: 85-90.
91. Lu SN, Lin TM, Chen CJ, Chen JS, Liaw YF, Chang WY, et al. A caseecontrol study of primary hepatocellular carcinoma in Taiwan. Cancer 1988; 62: 2051-5.
92. Ikeda M, Yoshimoto K, Yoshimura T, Kono S, Kato H, Kuratsune M. A cohort study on the possible association between broiled fish intake and cancer. Gann 1983; 74: 640-8.
93. Turati F, Trichopoulos D, Polesel J, Bravi F, Rossi M, Talamini R, et al. Mediterranean diet and hepatocellular carcinoma. J Hepatol 2014; 60: 606-11.
94. Li WQ, Park Y, McGlynn KA, Hollenbeck AR, Taylor PR, Goldstein AM, et al. Index-based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study. Hepatology 2014; 60: 588-97.
95. Romaguera D, Vergnaud AC, Peeters PH, van Gils CH, Chan DS, Ferrari P, et al. Is concordance with World Cancer Research Fund/American Institute for Cancer Research guidelines for cancer prevention related to subsequent risk of cancer? Results from the EPIC study. Am J Clin Nutr 2012; 96: 150-63.
96. George SM, Mayne ST, Leitzmann MF, Park Y, Schatzkin A, Flood A, et al. Dietary glycemic index, glycemic load, and risk of cancer: A prospective cohort study. Am J Epidemiol 2009; 169: 462-72.
97. Rossi M, Lipworth L, Maso LD, Talamini R, Montella M, Polesel J, et al. Dietary glycemic load and hepatocellular carcinoma with or without chronic hepatitis infection. Ann Oncol 2009; 20: 1736-40.
98. Lagiou P, Rossi M, Tzonou A, Georgila C, Trichopoulos D, La Vecchia C. Glycemic load in relation to hepatocellular carcinoma among patients with chronic hepatitis infection. Ann Oncol 2009; 20: 1741-5.
99. Fedirko V, Lukanova A, Bamia C, Trichopolou A, Trepo E, Nothlings U, et al. Glycemic index, glycemic load, dietary carbohydrate, and dietary fiber intake and risk of liver and biliary tract cancers in Western Europeans. Ann Oncol 2013; 24: 543-53.
100. Hu J, La Vecchia C, Augustin LS, Negri E, de Groh M, Morrison H, et al. Glycemic index, glycemic load and cancer risk. Ann Oncol 2013; 24: 245-51.
101. Vogtmann E, Li HL, Shu XO, Chow WH, Ji BT, Cai H, et al. Dietary glycemic load, glycemic index, and carbohydrates on the risk of primary liver cancer among Chinese women and men. Ann Oncol 2013; 24: 238-44.
102. Gallus S, Bertuzzi M, Tavani A, Bosetti C, Negri E, La Vecchia C, et al. Does coffee protect against hepatocellular carcinoma? Br J Cancer 2002; 87: 956-9.
103. Leung WW, Ho SC, Chan HL, Wong V, Yeo W, Mok TS. Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: A caseecontrol study. J Epidemiol Community Health 2011; 65: 556-8.
104. Gelatti U, Covolo L, Franceschini M, Pirali F, Tagger A, Ribero ML, et al. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: A caseecontrol study. J Hepatol 2005; 42: 528-34.
105. Montella M, Polesel J, La Vecchia C, Dal Maso L, Crispo A, Crovatto M, et al. Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer 2007; 120: 1555-9.
106. Ohfuji S, Fukushima W, Tanaka T, Habu D, Tamori A, Sakaguchi H, et al. Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: A caseecontrol study. Hepatol Res 2006; 36: 201-8.
107. Tanaka K, Hara M, Sakamoto T, Higaki Y, Mizuta T, Eguchi Y, et al. Inverse association between coffee drinking and the risk of hepatocellular carcinoma: A caseecontrol study in Japan. Cancer Sci 2007; 98: 214-8.
108. Kuper H, Tzonou A, Kaklamani E, Hsieh CC, Lagiou P, Adami HO, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000; 85: 498-502.
109. Wakai K, Kurozawa Y, Shibata A, Fujita Y, Kotani K, Ogimoto I, et al. Liver cancer risk, coffee, and hepatitis C virus infection: A nested caseecontrol study in Japan. Br J Cancer 2007; 97: 426-8.
110. Lai GY, Weinstein SJ, Albanes D, Taylor PR, McGlynn KA, Virtamo J, et al. The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. Br J Cancer 2013; 109: 1344-51.
111. Johnson S, Koh WP, Wang R, Govindarajan S, Yu MC, Yuan JM. Coffee consumption and reduced risk of hepatocellular carcinoma: Findings from the Singapore Chinese Health Study. Cancer Causes Control 2011; 22: 503-10.
112. Inoue M, Kurahashi N, Iwasaki M, Shimazu T, Tanaka Y, Mizokami M, et al. Effect of coffee and green tea consumption on the risk of liver cancer: Cohort analysis by hepatitis virus infection status. Cancer Epidemiol Biomarkers Prev 2009; 18: 1746-53.
113. Ohishi W, Fujiwara S, Cologne JB, Suzuki G, Akahoshi M, Nishi N, et al. Risk factors for hepatocellular carcinoma in a Japanese population: A nested caseecontrol study. Cancer Epidemiol Biomarkers Prev 2008; 17: 846-54.
114. Hu G, Tuomilehto J, Pukkala E, Hakulinen T, Antikainen R, Vartiainen E, et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology 2008; 48: 129-36.
115. Shimazu T, Tsubono Y, Kuriyama S, Ohmori K, Koizumi Y, Nishino Y, et al. Coffee consumption and the risk of primary liver cancer: Pooled analysis of two prospective studies in Japan. Int J Cancer 2005; 116: 150-4.
116. Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H, et al. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 2005; 93: 607-10.
117. Inoue M, Yoshimi I, Sobue T, Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: A prospective study in Japan. J Natl Cancer Inst 2005; 97: 293-300.
118. Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C. Coffee reduces risk for hepatocellular carcinoma: An updated metaanalysis. Clin Gastroenterol Hepatol 2013; 11: 1413-21. e1411.
119. Calle EE, Rodriguez C,Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-38.
120. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: A meta-analysis of cohort studies. Br J Cancer 2007; 97: 1005-8.
121. Calle EE, Kaaks R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-91.
122. La Vecchia C, Negri E, Decarli A, Franceschi S. Diabetes mellitus and the risk of primary liver cancer. Int J Cancer 1997; 73: 204-7.
123. Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000; 92: 1096-9.
124. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-80.
125. Bosetti C, Rosato V, Polesel J, Levi F, Talamini R, Montella M, et al. Diabetes mellitus and cancer risk in a network of caseecontrol studies. Nutr Cancer 2012; 64: 643-51.
126. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace. J Hepatol 2012; 56: 1384-91.
127. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: A consensus report. Diabetes Care 2010; 33: 1674-85.
128. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Combined estrogeneprogestogen contraceptives and combined estrogeneprogestogen menopausal therapy, vol. 91. Lyon: International Agency for Research on Cancer; 2007.
129. Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update 2010; 16: 631-50.
130. Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol 2007; 47: 506-13.
131. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000; 92: 1159-64.
132. Cai RL, Meng W, Lu HY, Lin WY, Jiang F, Shen FM. Segregation analysis of hepatocellular carcinoma in a moderately high-incidence area of East China. World J Gastroenterol 2003; 9: 2428-32.
133. Turati F, Edefonti V, Talamini R, Ferraroni M, Malvezzi M, Bravi F, et al. Family history of liver cancer and hepatocellular carcinoma. Hepatology 2012; 55: 1416-25.
134. Donato F, Gelatti U, Chiesa R, Albertini A, Bucella E, Boffetta P, et al. A case-control study on family history of liver cancer as a risk factor for hepatocellular carcinoma in North Italy. Brescia HCC Study. Cancer Causes Control 1999; 10: 417-21.
135. Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey JN, et al. The association of family history of liver cancer with hepatocellular carcinoma: A caseecontrol study in the United States. J Hepatol 2009; 50: 334-41.
136. Tanaka K, Hirohata T, Takeshita S, Hirohata I, Koga S, Sugimachi K, et al. Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: A caseecontrol study in Fukuoka, Japan. Int J Cancer 1992; 51: 509-14.
137. Yang Y, Wu QJ, Xie L, Chow WH, Rothman N, Li HL, et al. Prospective cohort studies of association between family history of liver cancer and risk of liver cancer. Int J Cancer 2014; 135: 1605-14.
138. Harrison SA, Bacon BR. Relation of hemochromatosis with hepatocellular carcinoma: Epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Med Clin North Am 2005; 89: 391-409.
139. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313: 1256-62.
140. Bradbear RA, Bain C, Siskind V, Schofield FD,Webb S, Axelsen EM, et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst 1985; 75: 81-4.
141. Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003; 125: 1733-41.
142. Stewart MF. Review of hepatocellular cancer, hypertension and renal impairment as late complications of acute porphyria and recommendations for patient follow-up. J Clin Pathol 2012; 65: 976-80.
143. Linet MS, Gridley G, Nyren O, Mellemkjaer L, Olsen JH, Keehn S, et al. Primary liver cancer, other malignancies, and mortality risks following porphyria: A cohort study in Denmark and Sweden. Am J Epidemiol 1999; 149: 1010-5.
144. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: Systematic review and meta-analysis. J Hepatol 2003; 39: 620-7.
145. Needham M, Stockley RA. Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax 2004; 59: 441-5.
146. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med 1986; 314: 736-9.
147. Zhou H, Ortiz-Pallardo ME, Ko Y, Fischer HP. Is heterozygous alpha-1-antitrypsin deficiency type PIZ a risk factor for primary liver carcinoma? Cancer 2000; 88: 2668-76.
148. White DL, Li D, Nurgalieva Z, El-Serag HB. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: A HuGE systematic review and meta-analysis. Am J Epidemiol 2008; 167: 377-89.
149. Chen KJ, Fan F, Wang Y, Wei GT, Hu L, Xu F. GSTT1 null genotype contributes to hepatocellular carcinoma risk: A metaanalysis. Tumour Biol 2014; 35: 213-8.
150. Song K, Yi J, Shen X, Cai Y. Genetic polymorphisms of glutathione S-transferase genes GSTM1, GSTT1 and risk of hepatocellular carcinoma. PLoS One 2012; 7: E48924.
151. Zhao Y, Wang Q, Deng X, Shi P, Wang Z. Quantitative assessment of the association between GSTP1 gene Ile105Val polymorphism and susceptibility to hepatocellular carcinoma. Tumour Biol 2013; 34: 2121-6.
152. Duan CY, Liu MY, Li SB, Ma KS, Bie P. Lack of association of EPHX1 gene polymorphisms with risk of hepatocellular carcinoma: A meta-analysis. Tumour Biol 2014; 35: 659-66.
153. Goedde HW, Agarwal DP, Fritze G, Meier-Tackmann D, Singh S, Beckmann G, et al. Distribution of ADH2 and ALDH2 genotypes in different populations. Hum Genet 1992; 88: 344-6.
154. Zhou D, Xiao L, Zhang Y, Xian J, Jiang J, Zong W, et al. Genetic polymorphisms of ALDH2 and ADH2 are not associated with risk of hepatocellular carcinoma among East Asians. Tumour Biol 2012; 33: 841-6.
155. Tian Z, Li YL, Zhao L, Zhang CL. CYP2E1 RsaI/PstI polymorphism and liver cancer risk among east Asians: A HuGE review and meta-analysis. Asian Pac J Cancer Prev 2012; 13: 4915-21.